IAP-0971 is under clinical development by Sunho (China) Biopharmaceutical and currently in Phase II for Lung Cancer. According to GlobalData, Phase II drugs for Lung Cancer have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IAP-0971’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IAP-0971 is under development for the treatment of solid tumor, non-small cell lung cancer (NSCLC), lung cancer, cervical cancer, head and neck squamous cell carcinoma, liver cancer, non muscle invasive bladder cancer (NMIBC), non-Hodgkin lymphoma and unspecified indication. The drug candidate is administered through intravesical, subcutaneous and intravenous drip. It acts by targeting PD1 and IL15. It is being developed based on Armed ImmunoCytokine (AIC) platform.
Sunho (China) Biopharmaceutical overview
Sunho (China) Biopharmaceutical (Sunho (China) Biopharmaceutical) is a healthcare service provider. It specializes in developing drugs for the treatment of cancer. Sunho (China) Biopharmaceutical is headquartered in Chengdu, China.
For a complete picture of IAP-0971’s drug-specific PTSR and LoA scores, buy the report here.